Why Source Pharmaceutical Products Through Switzerland

Switzerland is not the cheapest place from which to buy pharmaceutical products, and companies that source through Swiss partners are not looking for the lowest quotation. They are buying something else: a regulatory environment that other authorities recognise, a neutral trading position, and a way of working that reduces the number of surprises between contract and delivery.

Here is what that actually means in practice, and when it is worth it.

A regulatory reputation that travels

Swissmedic is a stringent regulatory authority, recognised as such internationally, and Switzerland participates in the European Pharmacopoeia system. For a company registering a product in a third market, the origin of the documentation matters: authorities tend to process a dossier supported by recognised standards with fewer questions than one that is not.

This does not remove the need to meet local requirements. It does reduce the friction of getting there.

Neutral ground between suppliers and markets

Much of the world’s active ingredient production is concentrated in Asia, while much of the demand sits in Europe, the Middle East, Latin America and Africa. Swiss trading companies have historically operated between the two, and the practical advantage is not geographic but contractual: a neutral jurisdiction, a stable legal framework and clear rules for international supply agreements.

For a buyer, this means a counterparty that can be held to a contract. For a manufacturer, it means access to markets without building a commercial structure in each of them.

What a sourcing partner adds beyond the product

The value of sourcing through an intermediary is often questioned, and reasonably so. It is justified when the intermediary does work the buyer would otherwise have to do:

• comparing several manufacturing sites against the same qualification criteria instead of approving the first available one
• checking which regulatory documentation exists for the specific destination market before a product is proposed
• verifying that a site can supply the required volumes and formats, not only a sample
• coordinating documentation and authority questions during registration
• maintaining a second source for products where interruption is not acceptable

It is not justified when the intermediary simply forwards a quotation. The distinction is visible in the first exchange: a partner who asks about the destination market, the dosage form and the expected volumes before answering is doing the work. One who sends a price list is not.

When Swiss sourcing makes sense, and when it does not

It makes sense for companies entering regulated markets with a product they have not manufactured before, for those who need documentation robust enough to survive an authority review, and for those who cannot afford a supply interruption on a critical product.

It makes less sense for a large manufacturer that already has qualified sites and an internal regulatory department. In that case the intermediary adds cost without adding capability, and it is better to work direct.

The Swiss structure in practice

Synergy Swiss Pharma was founded in 2015 and operates from Mendrisio, in the Italian-speaking canton of Ticino, a short distance from the Milan pharmaceutical cluster. The group covers the Asian market through Synergy Swiss Pharma Pte Ltd, with distribution across Asia for API and finished dosage forms and a new office opening in Malaysia.

Alongside product sourcing, the group includes Synergy Swiss Business Development for contract manufacturing and supply chain projects, and Synergy Swiss Engineering for the design and construction of pharmaceutical plants, including an Energy Advisory service for facilities looking to reduce operating costs.

The current product categories are listed under products, and common questions on markets and documentation are answered in the FAQ section.